GLP Watchdog

Does Cigna Pay for GLP-1 Medications? (2026)

Whether Cigna covers a GLP-1 depends on your specific plan; prior authorization is required, and members who are approved typically pay $25-$75 a month.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

Where Cigna stands[1]
Depends on the Plan
18,000,000 members · Prior authorization needed[1]
Depends on the Plan

Where Each Medication Stands[5]

MedicationWhat Cigna does
Wegovy (semaglutide)Cigna runs Wegovy through three separate doors, all under IP0206 SIII (effective 04/30/2026), all gated by prior authorization. Adults on the weight indication need to be >=18, to have at least 3 months of behavioral modification and dietary restriction already behind them, to carry BMI >=30 - or >=27 with any one of the 11 weight-related comorbidities Cigna lists. Those 11 fall into three groups: cardiometabolic (hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, coronary artery disease), respiratory and sleep (obstructive sleep apnea, asthma, COPD), and a remainder of MASLD/NAFLD, polycystic ovarian syndrome and knee osteoarthritis. The drug also has to be taken alongside a reduced-calorie diet. That buys 8 months. Renewal comes in 1-year blocks and is contingent on documented >=5% loss from baseline body weight. Adolescents from 12 up to 18 get the same 8-month first approval, but entry turns on the 95th percentile of BMI or higher, reached after a 3-month behavioral and dietary trial, and renewal turns on a >=1% BMI reduction rather than a weight percentage. The third door is the MACE risk-reduction pathway. An adult of 18 or over who has established cardiovascular disease and BMI >=27 qualifies on a 1-year approval, with no weight-loss condition attached at all.
Ozempic (semaglutide)Covered for type 2 diabetes per CNF 360 (last selected revision 01/07/2026). Step therapy gate: prior authorization is required whenever the record does not show an oral diabetes medication inside the previous 130 days, and for any patient under 18. CRITICAL: neither Rybelsus nor single-entity metformin counts toward that 130-day step. PA approval runs 1 year for patients 18 and over.
Zepbound (tirzepatide)IP0206 SV (effective 04/30/2026) governs Zepbound, and the adult weight gate is the same 4-prong test Cigna applies to Wegovy: age >=18, a 3-month behavioral and diet trial, lifestyle treatment alongside the drug, and BMI >=30 - or >=27 carrying one of the 11 comorbidities. 8 months on the first approval, then 1-year renewals against >=5% loss from baseline body weight. Sleep apnea is a separate route with a harder renewal than the weight one. Entry needs a sleep study showing AHI >=15, a BMI of 30 or more, and the absence of central sleep apnea and of Cheyne-Stokes breathing; the first approval runs 1 year. Keeping it requires >=10% body-weight loss after >=1 year AND a prescriber attestation that the OSA is stable. Dispensing is capped by CNF 840 and the cap does not move by strength: 4 pens or vials per 28 days at retail, 12 per 84 days through home delivery, no overrides.
Mounjaro (tirzepatide)Covered for type 2 diabetes per CNF 360 (last selected revision 01/07/2026). Step therapy gate: prior authorization is required whenever an oral diabetes medication does not appear inside the previous 130 days, and for any patient under 10 years of age. CRITICAL: neither Rybelsus nor single-entity metformin counts here either - the lookback has to contain some other oral antidiabetic. PA approval runs 1 year for patients 10 and over. The age floor moved recently: the policy History note records the minimum dropping from >=18 to >=10 on 01/07/2026.
Foundayo (orforglipron)Covered per IP0206 SII (effective 04/30/2026), on the same 4-prong adult gate Cigna applies to Wegovy and Zepbound: >=18, a 3-month behavioral and diet trial, BMI >=30 (or >=27 alongside one of the 11 listed weight-related comorbidities), and concomitant lifestyle treatment. The clock: 8 months on the initial approval, then 1 year at a time, each renewal contingent on documented >=5% loss from baseline body weight. One filing quirk to know - as of 02/25/2026 the standalone CNF 684 weight-loss PA policy still does not name the drug, so IP0206 is the source to cite.
Copay when it is covered$25-$75 / month

What a GLP-1 costs a Cigna member

At Cigna's typical copay of $25-$75 a month, a covered year of a GLP-1 costs $300 to $900. That is $3,288 to $3,888 less than a year of Wegovy bought for cash from NovoCare ($4,188), and Zepbound's LillyDirect price of $299 to $449 a month is further above it still.

The cheapest compounded option, Collective at $59/mo ($708 a year), lands inside the Cigna range, and 4 sellers charge no more than the $75 top of it, so for a member facing that copay a denial costs less than it sounds.

When Cigna covers the drug, a manufacturer savings card can bring a Wegovy or Zepbound fill down to $25, with each maker paying at most $100 a month.

Employers whose plans run through Cigna

Your employer decides much of this. Among the employers in our coverage checker, 1 use Cigna to run medical or pharmacy benefits: JPMorgan Chase. JPMorgan Chase's Wegovy position, for example: Covered with $50-$100 monthly copay.

After a Denial from Cigna

A Cigna denial leaves two routes: an appeal, and paying cash. With a prescription, a brand-name GLP-1 is generally an eligible HSA or FSA medical expense[3]. Compounded semaglutide and tirzepatide from licensed 503A pharmacies[4] cost far less than the brand; the cheapest sellers are listed below.

If a large employer self-funds your Cigna plan, ERISA rather than state insurance law applies and the employer decides whether anti-obesity drugs are covered[2]; the Summary Plan Description says which.

Cigna's PA criteria, quoted from the policy PDFs

Every Cigna GLP-1 PA clause is reproduced word for word in our guide: the CNF 840 quantity limits, the Wegovy MACE pathway, the Zepbound OSA pathway, the change making Mounjaro available from ≥10 years old, how Foundayo (orforglipron) is handled, the comorbidity list of 11 conditions, and the step-therapy rule running 130 days that excludes single-entity metformin. Read it in the Cigna GLP-1 Prior Authorization Guide.

Where to go if Cigna says no

Sellers that say they work with Cigna

Sellers that mention Cigna
#SellerCash priceVisit
1MDLivePrice not publishedVisit
2Enara HealthPrice not publishedVisit

The 8 cheapest cash-pay compounded GLP-1s

Cheapest cash-pay compounded GLP-1 sellers
#SellerMonthly priceVisit
1Collective
Compounded semaglutide
$59/moVisit
2Boston Medical Group
Compounded semaglutide
$66/moVisit
3OurView Health
Compounded semaglutide
$75/moVisit
4Ivim Health
Compounded semaglutide
$75/moVisit
5Embody
Compounded semaglutide
$79/moVisit
6Lean Meds
Compounded semaglutide
$79/moVisit
7NextMeds
Compounded semaglutide
$79/moVisit
8NuuVim
Compounded semaglutide
$79/moVisit

Every seller and price, side by side: compare all sellers.

Our picks

#ProviderScore
1Trimi HealthVisit
2EmbodyVisit
3CoreAge RxVisit
4bmiMDVisit
5Live VitalVisit

Frequently Asked Questions

Cigna runs Wegovy through three separate doors, all under IP0206 SIII (effective 04/30/2026), all gated by prior authorization. Adults on the weight indication need to be >=18, to have at least 3 months of behavioral modification and dietary restriction already behind them, to carry BMI >=30 - or >=27 with any one of the 11 weight-related comorbidities Cigna lists. Those 11 fall into three groups: cardiometabolic (hypertension, dyslipidemia, type 2 diabetes, cardiovascular disease, coronary artery disease), respiratory and sleep (obstructive sleep apnea, asthma, COPD), and a remainder of MASLD/NAFLD, polycystic ovarian syndrome and knee osteoarthritis. The drug also has to be taken alongside a reduced-calorie diet. That buys 8 months. Renewal comes in 1-year blocks and is contingent on documented >=5% loss from baseline body weight. Adolescents from 12 up to 18 get the same 8-month first approval, but entry turns on the 95th percentile of BMI or higher, reached after a 3-month behavioral and dietary trial, and renewal turns on a >=1% BMI reduction rather than a weight percentage. The third door is the MACE risk-reduction pathway. An adult of 18 or over who has established cardiovascular disease and BMI >=27 qualifies on a 1-year approval, with no weight-loss condition attached at all.
Covered for type 2 diabetes per CNF 360 (last selected revision 01/07/2026). Step therapy gate: prior authorization is required whenever the record does not show an oral diabetes medication inside the previous 130 days, and for any patient under 18. CRITICAL: neither Rybelsus nor single-entity metformin counts toward that 130-day step. PA approval runs 1 year for patients 18 and over.
IP0206 SV (effective 04/30/2026) governs Zepbound, and the adult weight gate is the same 4-prong test Cigna applies to Wegovy: age >=18, a 3-month behavioral and diet trial, lifestyle treatment alongside the drug, and BMI >=30 - or >=27 carrying one of the 11 comorbidities. 8 months on the first approval, then 1-year renewals against >=5% loss from baseline body weight. Sleep apnea is a separate route with a harder renewal than the weight one. Entry needs a sleep study showing AHI >=15, a BMI of 30 or more, and the absence of central sleep apnea and of Cheyne-Stokes breathing; the first approval runs 1 year. Keeping it requires >=10% body-weight loss after >=1 year AND a prescriber attestation that the OSA is stable. Dispensing is capped by CNF 840 and the cap does not move by strength: 4 pens or vials per 28 days at retail, 12 per 84 days through home delivery, no overrides.
Covered for type 2 diabetes per CNF 360 (last selected revision 01/07/2026). Step therapy gate: prior authorization is required whenever an oral diabetes medication does not appear inside the previous 130 days, and for any patient under 10 years of age. CRITICAL: neither Rybelsus nor single-entity metformin counts here either - the lookback has to contain some other oral antidiabetic. PA approval runs 1 year for patients 10 and over. The age floor moved recently: the policy History note records the minimum dropping from >=18 to >=10 on 01/07/2026.
Covered per IP0206 SII (effective 04/30/2026), on the same 4-prong adult gate Cigna applies to Wegovy and Zepbound: >=18, a 3-month behavioral and diet trial, BMI >=30 (or >=27 alongside one of the 11 listed weight-related comorbidities), and concomitant lifestyle treatment. The clock: 8 months on the initial approval, then 1 year at a time, each renewal contingent on documented >=5% loss from baseline body weight. One filing quirk to know - as of 02/25/2026 the standalone CNF 684 weight-loss PA policy still does not name the drug, so IP0206 is the source to cite.
Members who are approved typically pay $25-$75 a month, which is $300 to $900 over a year. A manufacturer savings card can lower that further when the plan covers the drug.
Appeal first: ask Cigna for the written denial and the criteria it applied, and have your prescriber answer them in a letter of medical necessity. If the appeal fails, the cheapest cash route is compounded semaglutide or tirzepatide, from Collective at $59/mo or Boston Medical Group at $66/mo. Sellers that say they work with Cigna include MDLive and Enara Health. A compounded drug is not FDA-approved as a finished product.

Glossary

The words sellers use, defined. Tap any term.

How coverage looks nationallyWork out the cash-pay difference
Sources & methodology — as of September 2026
  1. 1.KFF — Employer Health Benefits Annual Survey— Kaiser Family Foundation.
  2. 2.U.S. Department of Labor — ERISA and Employer Health Plans— U.S. Department of Labor, Employee Benefits Security Administration.
  3. 3.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.GLP Watchdog insurer coverage index (manually curated formulary data)— GLP Watchdog.